BACKGROUND AND PURPOSE: Encephaloduroarteriosynangiosis (EDAS) has become the main treatment for @entity7025 , a chronically progressive @entity432 in @entity1 . We aimed to assess the utility of perfusion-weighted MR imaging for evaluating hemodynamic changes before and after EDAS. METHODS: Thirteen @entity1 with angiographically confirmed @entity7025 who underwent EDAS were investigated, and results were compared with those of a control group (n = 5). Perfusion MR imaging was performed before and after EDAS by using a T2*-weighted contrast material-enhanced technique. Relative cerebral blood volume (rCBV) and @entity14782 ( @entity14782 ) maps were calculated. Relative ratios of rCBV and @entity14782 in the middle cerebral artery (MCA) and basal ganglia were measured and compared with those of the posterior cerebral artery (PCA). Changes in hemodynamic parameters between pre- and post-EDAS perfusion maps were investigated. RESULTS: The mean rCBV ratio of MCA to @entity4901 in the @entity1 group was slightly higher than that in the control group, without statistical significance. All 13 @entity1 showed a delayed @entity14782 in the MCA before EDAS compared with the control group (P =.0006), and the @entity14782 after EDAS was significantly reduced (P =.0002). In the basal ganglia, shortening of the @entity14782 was demonstrated before EDAS, but no significant change was observed after EDAS. CONCLUSION: Perfusion-weighted MR imaging can be applied for evaluating postoperative changes in cerebral blood flow in @entity7025 . Shortening of the @entity14782 in the MCA of the hemisphere operated on is a marker for the development of collateral circulation from the external carotid artery to the internal carotid artery.

Postoperative evaluation of XXXX with perfusion-weighted MR imaging: initial experience.

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient'] @entity14782 :: ('MESH:C564835', 'Disease') :: ['TTP', 'time to peak enhancement'] @entity7025 :: ('MESH:D009072', 'Disease') :: ['moyamoya disease'] @entity4901 :: ('CHEBI:36751', 'Chemical') :: ['PCA'] @entity432 :: ('MESH:D001157', 'Disease') :: ['cerebrovascular occlusive disease']
@entity7025 :: (MESH:D009072,Disease) :: ['moyamoya disease']
